NEW YORK, July 20, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021 (the “IPO”); and/or (ii) between June 16, 2021 and April 26, 2022, both dates inclusive (the “Class Period”), of the important September 12, 2022 lead plaintiff deadline.
SO WHAT: If you purchased Molecular Partners securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Molecular Partners class action, go to https://rosenlegal.com/submit-
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, the IPO documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, the complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the IPO documents and defendants made false and/or misleading statements and/or failed to disclose that: (1) ensovibep was less effective at treating COVID-19 than defendants had led investors to believe; (2) accordingly, the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization (“EUA”); (3) waning global rates of COVID-19 significantly reduced the Company’s chances of securing EUA for ensovibep; (4) as a product candidate, MP0310 (AMG 506), in development for the treatment of certain types of cancer, was less attractive to Amgen Inc. (“Amgen”) than defendants had led investors to believe; (5) accordingly, there was a significant likelihood that Amgen would return global rights of MP0310 to Molecular Partners; (6) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (7) as a result, the IPO documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Molecular Partners class action, go to https://rosenlegal.com/submit-
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/
Attorney Advertising. Prior results do not guarantee a similar outcome.
——————————
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
